145 related articles for article (PubMed ID: 12409827)
21. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
22. Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma.
Meyers N; Gérard C; Lemaigre FP; Jacquemin P
Sci Rep; 2020 Mar; 10(1):5241. PubMed ID: 32251323
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic correlation of beclin-1 expression in pancreatic ductal adenocarcinoma.
Kim HS; Lee SH; Do SI; Lim SJ; Park YK; Kim YW
Pathol Res Pract; 2011 Apr; 207(4):247-52. PubMed ID: 21420796
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
Dittert DD; Kielisch C; Alldinger I; Zietz C; Meyer W; Dobrowolski F; Saeger HD; Baretton GB
Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
[TBL] [Abstract][Full Text] [Related]
26. Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases.
Basturk O; Adsay V; Askan G; Dhall D; Zamboni G; Shimizu M; Cymes K; Carneiro F; Balci S; Sigel C; Reid MD; Esposito I; Baldaia H; Allen P; Klöppel G; Klimstra DS
Am J Surg Pathol; 2017 Mar; 41(3):313-325. PubMed ID: 27984235
[TBL] [Abstract][Full Text] [Related]
27. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.
Karanjawala ZE; Illei PB; Ashfaq R; Infante JR; Murphy K; Pandey A; Schulick R; Winter J; Sharma R; Maitra A; Goggins M; Hruban RH
Am J Surg Pathol; 2008 Feb; 32(2):188-96. PubMed ID: 18223320
[TBL] [Abstract][Full Text] [Related]
28. Reduced expression of epidermal growth factor receptor related protein in gastric cancer.
Moon WS; Tarnawski AS; Chai J; Yang JT; Majumdar AP
Gut; 2005 Feb; 54(2):201-6. PubMed ID: 15647181
[TBL] [Abstract][Full Text] [Related]
29. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
[TBL] [Abstract][Full Text] [Related]
30. Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells.
Pan Z; Erkan M; Streit S; Friess H; Kleeff J
Int J Oncol; 2009 Oct; 35(4):823-8. PubMed ID: 19724918
[TBL] [Abstract][Full Text] [Related]
31. Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance.
Wang L; Xiong L; Wu Z; Miao X; Liu Z; Li D; Zou Q; Yang Z
World J Surg Oncol; 2018 Jan; 16(1):11. PubMed ID: 29347944
[TBL] [Abstract][Full Text] [Related]
32. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.
Xie ZB; Zhang YF; Jin C; Mao YS; Fu DL
J Exp Clin Cancer Res; 2019 Feb; 38(1):75. PubMed ID: 30760292
[TBL] [Abstract][Full Text] [Related]
33. Expression of epidermal growth factor-receptor related protein (ERRP) in human colorectal carcinogenesis.
Jaszewski R; Levi E; Sochacki P; Frank J; Kucuk O; Axelrod BN; Majumdar AP
Cancer Lett; 2004 Sep; 213(2):249-55. PubMed ID: 15327841
[TBL] [Abstract][Full Text] [Related]
34. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.
Grützmann R; Lüttges J; Sipos B; Ammerpohl O; Dobrowolski F; Alldinger I; Kersting S; Ockert D; Koch R; Kalthoff H; Schackert HK; Saeger HD; Klöppel G; Pilarsky C
Br J Cancer; 2004 Mar; 90(5):1053-8. PubMed ID: 14997207
[TBL] [Abstract][Full Text] [Related]
35. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.
An W; Ben QW; Chen HT; Zheng JM; Huang L; Li GX; Li ZS
Ann Surg Oncol; 2012 Nov; 19(12):3971-8. PubMed ID: 22622471
[TBL] [Abstract][Full Text] [Related]
36. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
Merati K; said Siadaty M; Andea A; Sarkar F; Ben-Josef E; Mohammad R; Philip P; Shields AF; Vaitkevicius V; Grignon DJ; Adsay NV
Am J Clin Oncol; 2001 Oct; 24(5):447-52. PubMed ID: 11586094
[TBL] [Abstract][Full Text] [Related]
37. Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth.
Moon WS; Chang KJ; Majumdar AP; Tarnawski AS
Digestion; 2004; 69(4):219-24. PubMed ID: 15205570
[TBL] [Abstract][Full Text] [Related]
38. Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer.
Byers JT; Paniccia A; Kaplan J; Koenig M; Kahn N; Wilson L; Chen L; Schulick RD; Edil BH; Zhu Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1574-9. PubMed ID: 25519928
[TBL] [Abstract][Full Text] [Related]
39. Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
Körner M; Hayes GM; Rehmann R; Zimmermann A; Friess H; Miller LJ; Reubi JC
Am J Pathol; 2005 Oct; 167(4):959-68. PubMed ID: 16192632
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.
Giaginis C; Tsourouflis G; Zizi-Serbetzoglou A; Kouraklis G; Chatzopoulou E; Dimakopoulou K; Theocharis SE
Pathol Oncol Res; 2010 Jun; 16(2):267-76. PubMed ID: 19949912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
